Matthew A. Spear - 01 Mar 2022 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Mar 2022, 18:28:00 UTC
Previous filing: 08 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+50,000	+81%	$0.000000	111,485	01 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+72,568		$0.000000	72,568	01 Mar 2022	Common Stock	72,568	$3.42	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.